Does Pfizer really want Bristol-Myers? Likely, says one analyst. What's it waiting for?

2nd October 2017 Uncategorised 0

Investors have had a pointed question for Credit Suisse analysts lately: Is Pfizer buying Bristol-Myers Squibb a question of when, not if? The way analyst Vamil Divan sees it, maybe so.

More: Does Pfizer really want Bristol-Myers? Likely, says one analyst. What's it waiting for?
Source: fierce